EP3784257A1 - Cellules différenciées de cellules souches mésenchymateuses pour le traitement de lésions dermiques - Google Patents

Cellules différenciées de cellules souches mésenchymateuses pour le traitement de lésions dermiques

Info

Publication number
EP3784257A1
EP3784257A1 EP19722530.3A EP19722530A EP3784257A1 EP 3784257 A1 EP3784257 A1 EP 3784257A1 EP 19722530 A EP19722530 A EP 19722530A EP 3784257 A1 EP3784257 A1 EP 3784257A1
Authority
EP
European Patent Office
Prior art keywords
cells
population
hla
phenotype
isolated cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19722530.3A
Other languages
German (de)
English (en)
Inventor
Marcela GARCIA
Guillermo Tomas BUERO
Edgardo Delfino Carosella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Nacional de La Plata
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Universidad Nacional de La Plata
Commissariat a lEnergie Atomique CEA
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Nacional de La Plata, Commissariat a lEnergie Atomique CEA, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Universidad Nacional de La Plata
Publication of EP3784257A1 publication Critical patent/EP3784257A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the invention pertains to the field of therapeutic treatment of dermal lesions, based on cells differentiated from mesenchymal stem cells.
  • MSCs have received considerable attention for modulating wound repair (Bajada et al., J Tissue Eng Regen Med., 2(4): 169-83), 2008).
  • MSCs have been examined in skin repair and regeneration after various acute and chronic skin injuries, such as acute incisional and excisional wounds, diabetic skin ulcers, radiation burns, and thermal burns (Wu et al, 25(l0):2648-59, 2007; Lataillade et al, Regen Med., 2(5):785-94, 2007; Vojtassak et al., Neuro Endocrinol Lett., 27(Suppl 2): 134—7), 2006).
  • the inventors have set up a method that enables the differentiation of mesenchymal stem cells into a population of cells which is homogenous for the phenotype CD44 + , CD73 + , CD29 + , CDl05 + , CD90 + , HLA-G + and HLA-DR .
  • the population of cells possess immunomodulation capacity (as supported by the immunomodulation capacity test detailed in the experimental part), and further is particularly efficient in the treatment of dermic lesions such as ulcers, usually difficult to treat.
  • the population of cells of the invention promotes wound healing, improving the rapidity of cicatrization and enabling complete recovery, that is to say regeneration of the tissue.
  • These properties are of particular interest in the treatment of dermic lesions, in particular ulcers, such as leg ulcer, and chronic fistulas.
  • the beneficial properties of the population of cells according to the invention resides, at least in art, in the cells expressing HLA-G.
  • the HLA-G molecule is a non-classical class I HLA molecule which has effective immunosuppressive properties, and has been shown to play an essential role in feto-maternal tolerance and allogenic tissue graft tolerance.
  • Two cellular membrane receptors interact with HLA-G: ILT2 and ILT4.
  • the ILT2 receptor is expressed on the monocytes/macrophages, dendritic cells, B, and T lymphocytes particularly in the cytotoxic T subset and natural Killer cells.
  • the ILT4 receptor is expressed on myeloid cells: monocytes, dendritic and APC cells. The interaction between HLA-G and these receptors confers a strong immunosuppressive activity, capable to inhibit the immune response at different levels.
  • the cells resulting from the method of differentiation of the invention do not express HLA-DR, and as a result are not limited to autologous therapy and can be used in heterologous therapy, that is to say applied to patients having a different HLA-DR than the HLA-DR of the donor of mesenchymal stem cells.
  • the invention pertains to a population of isolated cells which is homogenous for the phenotype CD44 + , CD73 + , CD29 + , CDl05 + , CD90 + , HLA-G + and HLA-DR .
  • CD29 refers to the human cell-surface protein CD29, also known as Integrin subunit beta-l, which is a product of the human TTGB1 gene (Entrez gene ID: 3688).
  • a cell having a CD29 + phenotype is a cell expressing on its surface the CD29 protein as defined above.
  • Expression of a protein on the surface of a cell can easily be assessed using established techniques known in the art, such as for instance flow cytometry.
  • CD44 refers to the human cell-surface glycoprotein CD44, which is a product of the human CD44 gene (Entrez gene ID: 960).
  • a cell having a CD44 + phenotype is a cell expressing on its surface the CD44 glycoprotein as defined above.
  • CD73 refers to the human cell-surface antigen CD73, also known as ecto-5'-nucleotidase or 5'-nucleotidase (5'-NT), which is a product of the human NT5E gene (Entrez gene ID: 4907).
  • a cell having a CD73 + phenotype is a cell expressing on its surface the CD73 antigen as defined above.
  • CD90 refers to the human N-glycosylated, glycophosphatidylinositol (GPI) cell surface protein CD105, also known as Thy-l, which is a product of the human THY1 gene (Entrez gene ID: 7070).
  • GPI glycophosphatidylinositol
  • a cell having a CD90 + phenotype is a cell expressing on its surface the CD90 protein as defined above.
  • CD105 refers to the human cell-surface glycoprotein CD105, also known as Endoglin, which is a product of the human ENG gene (Entrez gene ID: 2022).
  • a cell having a CDl05 + phenotype is a cell expressing on its surface the CD 105 protein as defined above.
  • the terms“HLA-G” refer to any of the non-classical class I HLA antigen (immune tolerant protein) cell surface proteins HLA-G, expressed by the human HLA-G gene (Entrez gene ID: 3135).
  • the human HLA-G gene encodes both the membrane-bounds proteins HLA-G1, HLA-G2, HLA-G3, HLA-G4 and the soluble proteins HLA-G5, HLA-G6, HLA-G7.
  • the terms“HLA-G” encompass the human proteins HLA-G1, HLA-G2, HLA-G3, HLA-G4.
  • a cell having a HLA-G + phenotype is a cell expressing on its surface any of the human proteins HLA-G 1, HLA-G2, HLA-G3, HLA-G4, as defined above.
  • HLA-DR refers to the human MHC class II cell surface receptors HLA-DR, a family of ab heterodimerd formed of an a-chain which does not vary, paired with any of the b-chain encoded by the genes of any of the loci HLA- DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5.
  • the a-chain is thus encoded by the HLA-DRA locus (Entrez gene ID: 3122).
  • the b-chain may result from the expression of HLA-DRB1 locus (Entrez gene ID: 3123), the HLA-DRB3 locus (Entrez gene ID: 3125), the HLA-DRB4 locus (Entrez gene ID: 3126), or the HLA-DRB5 locus (Entrez gene ID: 3127).
  • a cell having a HLA-DR phenotype is a cell which does not express on its surface any of the proteins encoded by the HLA-DRA, the HLA- DRB1, the HLA-DRB3, the HLA-DRB4, or the HLA-DRB5 locus.
  • a population of cells is considered as“homogenous for the phenotype CD44 + , CD73 + , CD29 + , CDl05 + , CD90 + , HLA-G + and HLA-DR” when said population of cells consists essentially of cells having the phenotype CD44 + , CD73 + , CD29 + , CDl05 + , CD90 + , HLA-G + and HLA-DR .
  • the population of cells of the invention is characterized in that:
  • the population of cells of the invention is characterized in that at least 90%, preferably at least 95%, yet preferably at least 99% of the cells within the population have the phenotype CD44 + , CD73 + , CD29 + , CDl05 + , CD90 + , HLA-G + , and all of the cells have the phenotype HLA-DR .
  • the population of cells of the invention is characterized in that all of the cells within the population have the phenotype CD44 + , CD73 + , CD29 + , CD105 1 , CD90 + , HLA-G + and HLA-DR .
  • the population of cells according to the invention is a population of pluripotent cells.
  • the population of cells according to the invention is derived, advantageously by differentiation, from a population of MSCs, more preferably from a population of MSCs obtained from Wharton’s jelly, yet preferably from a population of MSCs obtained from human umbilical cord’s Wharton’s jelly.
  • the terms“mesenchymal stem cells” or“MSCs” refer to multipotent stem cells, able to differentiate into a variety of cell types, present in biological tissues of mesenchyme origin, such as umbilical cord tissue, preferably Wharton's jelly and the umbilical cord blood, bone marrow, adipose tissue, the developing tooth bud of the mandibular third molar, and amniotic fluid.
  • the population of MSCs according to the invention is homogenous for the phenotype CD90 + , CD73 + , CDl05 + , CDl66 + , CDl72alpha + , CDl7l + , CDl lb , CD14 , CD 19 , CD34 , CD45 , CD79A-, CD309 and HLA-DR .
  • CD14 refers to the human membrane- bound protein mCDl4, which is a product of the human CD 14 gene (Entrez gene ID: 929).
  • a cell having a CD 14 phenotype is a cell that does not express the CD 14 protein as defined above on its surface.
  • CD19 refers to the human membrane- bound protein CD19, which is a product of the human CD19 gene (Entrez gene ID: 930).
  • a cell having a CD 19 phenotype is a cell that does not express the CD 19 protein as defined above on its surface.
  • CD34 refers to the human cell surface glycoprotein CD34, which is encoded by the human CD34 gene (Entrez gene ID: 947).
  • a cell having a CD34 phenotype is a cell that does not express the CD34 protein as defined above on its surface.
  • CD45 refers to the human antigen CD45, also known as Protein tyrosine phosphatase, receptor type, C (PTPRC), which is encoded by the human PTPRC gene (Entrez gene ID: 5788).
  • PTPRC Protein tyrosine phosphatase, receptor type, C
  • a cell having a CD45 phenotype is a cell that does not express the CD45 protein as defined above on its surface.
  • CD79A refers to alpha chain of the human transmembrane protein CD79, also known as B-cell antigen receptor complex- associated protein alpha chain, which is encoded by the human CD79A gene (Entrez gene ID: 973).
  • a cell having a CD79A phenotype is a cell that does not express the CD79A protein as defined above on its surface.
  • CD166 refers to the human transmembrane glycoprotein CD 166 antigen, which is encoded by the human ALCAM gene (Entrez gene ID: 214).
  • a cell having a CD166 1 phenotype is a cell expressing on its surface the CD 166 protein as defined above.
  • the term“CD172alpha + ” refers to the human Signal regulatory protein alpha (SIRPa), which is encoded by the human SIRPA gene (Entrez gene ID: 140885).
  • SIRPa Signal regulatory protein alpha
  • a cell having a CDl72alpha + phenotype is a cell expressing on its surface the CDl72alpha + protein as defined above.
  • CD309 refers to the human membrane- bound vascular endothelial growth factor receptor 2, also known as Kinase insert domain receptor (KDR), which is a product of the human KDR gene (Entrez gene ID: 3791).
  • KDR Kinase insert domain receptor
  • a cell having a CD309 phenotype is a cell that does not express the CD309 protein as defined above on its surface.
  • CDllb refers to the human Integrin alpha M protein, also known as Complement receptor 3 A (CR3A), which is a product of the human KDR gene (Entrez gene ID: 3684).
  • a cell having a CDl lb phenotype is a cell that does not express the CDl lb protein as defined above on its surface.
  • the terms“MSCs obtained from Wharton’s jelly” refer to a population of MSCs homogenous for the phenotype CD90+, CD73+, CD105+, CD166+, CDl72alpha+, CD171+, CDl lb-, CD14-, CD19-, CD34-, CD45-, CD79a-, CD309- and HLA-DR-, and isolated from Wharton’s jelly.
  • Wharton’s Jelly also referred to in the art as substantia gelatinea funiculi umbilicalis is a gelatinous substance derived from extra-embryonic mesoderm, present within the umbilical cord.
  • Wharton’s Jelly is mostly comprised of mucopolysaccharides, such as hyaluronic acid and chondroitin sulfate, and has been shown to comprise MSCs, and more particularly MSCs having sternness and immune properties.
  • MSCs harvested from the umbilical cord’s Wharton’s jelly are expected to exhibit a much more proliferative, immunosuppressive, and even therapeutically active stem cells than those isolated from older, adult tissue sources such as the bone marrow or adipose tissue.
  • the terms“MSCs obtained from the umbilical cord’s Wharton’s jelly” refer to a population of MSCs homogenous for the phenotype CD90 + , CD73 + , CDl05 + , CDl66 + , CDl72alpha + , CDl7l + , CDl lb , CD14 , CD19 , CD34 , CD45 , CD79a , CD309 and HLA-DR , and isolated from the umbilical cord’s Wharton’s jelly, preferably from umbilical cord’s Wharton’s jelly of human origin.
  • a population of cells is considered as homogenous for the phenotype CD90 + , CD73 + , CDl05 + , CDl66 + , CDl72alpha + , CDl7l + , CD11B , CD14 , CD 19 , CD34 , CD45 , CD79A , CD309 and HLA-DR when:
  • - at least 90%, preferably at least 95%, yet preferably at least 99% of the cells within the group have the phenotype CD309
  • - at least 90%, preferably at least 95%, yet preferably at least 99% of the cells within the group have the phenotype HLA-DR .
  • a population of cells is considered as homogenous for the phenotype CD90 + , CD73 + , CDl05 + , CDl66 + , CDl72alpha + , CDl7l + , CD11B , CD 14 , CD19 , CD34 , CD45 , CD79A , CD309 and HLA-DR when at least 90%, preferably at least 95%, yet preferably at least 99% of the cells within the group have the phenotype CD90 + , CD73 + , CDl05 + , CDl66 + , CDl72alpha + , CDl7l + , CD11B , CD14 , CD 19 , CD34 , CD45 , CD79A , CD309 and HLA-DR .
  • the population of cells of the invention may conveniently be obtained by implementing the following method of differentiation, using MSCs, preferably of MSCs obtained from Wharton’s jelly, more preferably of MSCs obtained from the umbilical cord’s Wharton’s jelly, yet preferably MSCs obtained from human umbilical cord’s Wharton’s jelly, as starting material.
  • MSCs preferably of MSCs obtained from Wharton’s jelly, more preferably of MSCs obtained from the umbilical cord’s Wharton’s jelly, yet preferably MSCs obtained from human umbilical cord’s Wharton’s jelly, as starting material.
  • the invention further pertains to a method of differentiation, comprising the successive steps of:
  • MSCs cells can easily be isolated according to methods known in the art, from tissues known to contain them such as indicated above. Further, MSCs may be obtained in particular from Wharton’s Jelly, by any of the method known in the art. Such methods have been thoroughly disclosed for instance by McElreavey K.D. el al., ( Biochem . Soc. Trans:, 19:29S, 1991), Kadner A. el al., ( Eur . J. Cardio-Thorac. Surg:, 25:635-641, 2004), Mitchell K.E. el al., ( Stem Cells, 21:50-60, 2003), and Kim et al, (Int J Mol ScL; 14(6): 11692, 2013).
  • the person skilled in the art may easily verify that the population of MSCs is actually homogenous for the phenotype CD90 + , CD73 + , CD105 1 , CD166 1 , CDl72alpha + , CD171 1 , CD11B , CD14 , CD19 , CD34 , CD45 , CD79A , CD309 and HLA-DR , using the methods disclosed above.
  • step b) of the method of the invention it should be construed that the cells are cultured in appropriate conditions of temperature, humidity and atmosphere composition (i.e., 0 2 and C0 2 in particular). For instance, the cells may be incubated at 37°C in a humid atmosphere, in the presence of 5% of C0 2 .
  • the term“appropriate culture medium” refers to any cell culture medium appropriate for the differentiation of MSCs cells.
  • the appropriate culture medium comprises platelet lysate, such as described in Luzzani et al, yet preferably, the appropriate culture medium comprises alpha MEM base medium supplemented with 10% of platelet lysate.
  • the appropriate culture medium is xeno-free, in other terms all components of the cell culture medium are derived from the same organism, preferably derived from human origin.
  • the appropriate culture medium does not contain products of animal origin other than human.
  • the cells are cultured up until they form a population of cells which comprises a sufficient number of cells having the phenotype CD44 + , CD73 + , CD29 + , CDl05 + , CD90 + , HLA-G + and HLA-DR , for instance a population wherein more than 50% of the cells have the phenotype CD44 + , CD73 + , CD29 + , CDl05 + , CD90 + , HLA-G + and HLA-DR .
  • the cells are cultured up until they form a population of cells which is homogenous for the phenotype CD44 + , CD73 + , CD29 + , CDl05 + , CD90 + , HLA-G + and HLA-DR .
  • the culture of step b) is performed for at least 14 days, preferably for between 14 and 40 days, yet preferably for between 20 and 35 days.
  • the population of cells may already contain enough cells having the phenotype CD44 + , CD73 + , CD29 + , CDl05 + , CD90 + , HLA-G + and HLA-DR , in which case step c) may easily be performed by simply collecting the cultured cells.
  • the person skilled in the art may add steps of selecting the cells having the appropriate phenotype.
  • the population of cells of the invention possesses immunomodulation capacity, which, without being bound by theory, is likely to stem from their HLA-G + phenotype.
  • the person skilled in the art may add to the method of the invention a further step comprising an immunomodulation capacity test.
  • the method of the invention comprises a further step of assessing that the population of cells from step c) has immunomodulation capacity.
  • the method of the invention does not comprise any enzymatic digestion step, allowing to preserve the population of MSCs.
  • the term“immunomodulation capacity” should be construed as generally understood in the field, i.e., as the ability to suppress the proliferation of lymphocytes, preferably of CD4 and CD8 T lymphocytes. Such capacity can be assayed using methods well known in the art, such as that disclosed in the experimental part.
  • the population of cells of the invention is co-cultured with PBMCs previously pre-stimulated with concanavalin-A, in a medium appropriate for the culture of lymphocytes, such as RPMI-1640 supplemented with 10% FBS, said medium further comprising interleukin-2.
  • lymphocytes preferably of CD4 and CD8 T lymphocytes
  • control conditions i.e., culture of PBMCs in the absence of the cells of the invention.
  • a population of cells is considered has having “immunomodulation capacity” when it limits or suppress the proliferation of lymphocytes, preferably of CD4 and CD8 T lymphocytes, in comparison with said control.
  • the method of the invention comprises a further step of selecting population of cells which has immunomodulation capacity as defined above.
  • the population of cells according to the invention may either be used directly, preferably for their therapeutic use as detailed thereafter, or advantageously be frozen and stored for later use.
  • Cells may be frozen using usual methods known in the art, and are preferably stored suspended in a medium comprising alpha MEM, platelet Lysate and DMSO, at a temperature of -20°C or less, preferably of -80°C of less.
  • a medium comprising alpha MEM, platelet Lysate and DMSO
  • Another aspect of the invention relates to a pharmaceutical composition, comprising a population of isolated pluripotent stem cells according to the invention, and, preferably, a pharmaceutically acceptable carrier.
  • Suitable vehicles or carriers include any pharmaceutically acceptable vehicle such as buffering agents, stabilizing agents, diluents, salts, preservatives, emulsifying agents, sweeteners, etc.
  • vehicle typically comprises an isotonic aqueous or non-aqueous solution, which may be prepared according to known techniques.
  • Suitable solutions include buffered solutes, such as phosphate buffered solution, chloride solutions, Ringer’s solution, and the like.
  • a further aspect of the invention relates to the population of cells, or compositions comprising thereof according to the invention for use as a medicament.
  • the population of cells or composition comprising thereof according to the invention is for use in the treatment of lesions of biological tissues.
  • biological tissues refer to human bodily tissues and preferably epitheliums, preferably the dermis, epidermis, and/or subcutaneous tissue.
  • the population of cells or composition comprising thereof according to the invention is for improving regeneration of said lesion.
  • the term“regeneration” refers to the formation of new tissue in place of the injured tissue.
  • regeneration involves the formation of new tissue including formation of structures usually present in such tissues such as hair follicles and glands.
  • the term“regeneration” is not equivalent to the term“cicatrization”, the latter involving only the replacement of normal tissue with connective tissue without formation of new as hair follicles and glands.
  • the population of cells or composition comprising thereof according to the invention is for use in the treatment of lesions of the epithelium tissue, yet preferably lesions of the dermis, epidermis, and/or subcutaneous tissue.
  • the population of cells or composition comprising thereof according to the invention is for use in the treatment of chronic lesions, preferably chronic lesions of the dermis, epidermis, and/or subcutaneous tissue, yet preferably ulcers.
  • the terms“ulcers” are to be construed according to the general meaning in the art, that is to say as a sore on the skin or a mucous membrane, accompanied by the disintegration of tissue, occurring as a result of impaired blood circulation, bacterial or viral infections, fungal infections or cancers.
  • the epidermal lesions are epidermal lesions associated with chronic leg ulcers, epidermal lesions associated with decubitus ulcers, and chronic fistulas.
  • the terms“chronic leg ulcers” are to be construed according to the general meaning in the art, that is to say as the spontaneous or accidental tissue lesions in a varicose leg, for more than fifteen days, with no signs of healing despite conventional treatment, said lesions occurring as a result of a deep venous thrombosis.
  • the terms“decubitus ulcers” are to be construed according to the general meaning in the art, that is to say as the tissue lesions to the skin and/or underlying tissue that usually occur over a bony prominence as a result of pressure, or pressure in combination with shear and/or friction.
  • the invention also provides a method for the treatment of lesions, more preferably the treatment of lesions of the epithelium tissue, yet preferably epidermal lesions, in a subject, comprising: administering to said subject a population of cells or a composition comprising thereof according to the invention.
  • the population of cells or composition comprising thereof according to the invention is administered in a therapeutically effective amount.
  • therapeutically effective amount it is hereby referred to an amount which is, over time, sufficient to at least improve the disease, in the context of the invention improve the lesion, preferably improve cicatrization and regeneration of the lesion.
  • said amount can be adjusted by the skilled artisan, depending on the pathological condition, the subject, the duration of treatment, the presence of other active ingredients, in order to obtain the desired therapeutic response.
  • the population of cells or composition comprising thereof according to the invention is administered through the parenteral route, preferably via intravenous, intramuscular, subcutaneous or intradermal administration.
  • the population of cells or composition comprising thereof according to the invention is administered is administered through subcutaneous or intradermal administration, advantageously intradermal administration.
  • the population of cells or composition comprising thereof according to the invention is administered by injection.
  • injection refers to the continuous administration of liquid or medication in a subject, via intradermal or subcutaneous application, lasting less than 15 minutes. Injection typically involves the administration of said fluid or medication through a needle or a catheter.
  • the invention also comprises other provisions that will emerge from the following examples of implementation, which may not be construed as limiting the scope of the invention.
  • Figure 1 Picture of the initial lesion obtained using disposable dermatology biopsy punch on mice. This lesion involves epidermis, dermis and cellular subcutaneous tissues. The lesion size is about 0.7 mm of diameter.
  • Figure 2 Pictures of the evolution of wound healing.
  • the initial lesion as illustrated in figure 1 was either not treated (group 1), treated with an MDC injection from DMC of murine umbilical cord (group 2) or treated with MDC injection from DMC of human umbilical cord (group 3).
  • group 1 The initial lesion as illustrated in figure 1 was either not treated (group 1), treated with an MDC injection from DMC of murine umbilical cord (group 2) or treated with MDC injection from DMC of human umbilical cord (group 3).
  • One week after initiation of the treatment pictures were taken for each of the 3 groups.
  • Figure 2. A is representative of group 1, i.e., controls animals without treatment. The lesion began cicatrize but show some cicatricial blood clot and no pilous growth.
  • Figure 2.B is representative of group 2, i.e., mice treated with intradermal injection of DMC from murine umbilical cords on the edges of the injury.
  • Figure 2.C is representative of the group 3, i.e., mice treated with intradermal injection of DMC from human umbilical cords on the edges of the injury. Skin regeneration could be observed, with formation of new hair follicles.
  • Mesenchymal stem cells were obtained from human umbilical cords using the following protocol.
  • Human umbilical cords obtained from discarded placentas are placed in DMEM culture medium. Cords are chopped in 5 mm length items. The cuts are made in the middle part of the length of the umbilical cord. Every portion, about 5 mm long, is sagittally cut in the amniotic membrane and the mesenchymal mucoid connective tissue (Wharton Jelly) is exposed. The mucoid connective perivascular tissue and the umbilical’s vessels are extracted. The gelatin face of Wharton jelly is put down in direct contact with the cell culture plate, and cultured in the conditions described in Luzzani et al, that is to say in a culture medium comprising alpha MEM base medium supplemented with 10% of platelet lysate.
  • DMC are characterized by surface markers for DMC typical antigen (CD44 + , CD73 + , CD29 + , CDl05 + , CD90 + , HLA-G + , HLA-DR ), and cells positive for this phenotype are selected using flow cytometry.
  • Lymphocytes proliferation is analyzed by in vitro inhibition. Briefly, heparinized blood samples were resuspended in PBS (1:1). Diluted blood was then carefully layered on top of the ficoll (Histopaque-l077, Sigma, US) at a ratio 1.5:1 and centrifuged at 800g for 30 minutes. The huffy coat layer containing mononuclear cells was aspirated, and the PBMCs were then either cultured for immediate use in RPMI-1640 (Gibco, US) supplemented with 10% FBS, or frozen for later use.
  • RPMI-1640 Gibco, US
  • PBMCs were stained with CFSE (Life Technologies, US) and pre-stimulated with concanavalin-A (Sigma, US) for 24 hs. Then, one-day stimulated PBMCs (i.e., peripheral blood mononuclear cells) were washed with PBS and co-cultered with DMCs for 96 hours in RPMI-1640 supplemented with 10% FBS, 10 ng/ml anti-CD3 antibody (clone UCHT1) and 300 IU/ml interleukin-2 (both from R&D Systems, US). PBMCs where then collected and analyzed by flow cytometry.
  • CFSE Life Technologies, US
  • concanavalin-A Sigma, US
  • DMC are frost in cryotubes and stored in the Master bank.
  • the cells are washed with PBS, recovered with trypsin.
  • the PBS is replaced with DMEM + 10% BFS to inactivate trypsin.
  • Cells are washed and centrifuged at 1000 G for 5 minutes.
  • the obtained pellets are resuspended in alphaMEM + 20 % platelet lysate + 10 % DMSO.
  • the cryotubes were placed at a final concentration of 1 x 106 DMC in 1 ml.
  • Cells are defrost and culture for expansion, and passaged (until a maximum of 6 passages).
  • Cells may be used directly or frost for storage in view of future uses.
  • mice In vivo tests on mice.
  • mice C3H/S Three groups of inmunocompetent mice C3H/S were constituted, each comprising 6 mice.
  • FIG. 1 illustrates the lesion obtained.
  • Group 2 Dorsal lesion treated with perilesional intradermal injection of 250.000 DMC/0.1 ml PBS, differentiated from MSC from murine umbilical cords.
  • Group 3 Dorsal lesion treated with perilesional injection of 250.000 DMC/0.1 ml PBS, differentiated from MSC from human umbilical cords.
  • Luzzani C Neiman G, Garate X, et al., A therapy- grade protocol for differentiation of pluripotent stem cells into mesenchymal stem cells using platelet lysate as supplement.
  • Mitchell K.E. Weiss M.L., Mitchell B.M., Martin P., Davis D., Morales L., Helwig B., Beerenstrauch M., Abou-Easa K., Hildreth T., el al., Matrix cells from wharton’s jelly form neurons and glia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une population de cellules isolées qui est homogène pour le phénotype CD44+, CD73+, CD29+, CD105+, CD90+, HLA-G+ et HLA-DR-, ou des compositions les comprenant, à utiliser en tant que médicament, ainsi que des méthodes de préparation de telles cellules.
EP19722530.3A 2018-04-23 2019-04-23 Cellules différenciées de cellules souches mésenchymateuses pour le traitement de lésions dermiques Pending EP3784257A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305501.1A EP3560504A1 (fr) 2018-04-23 2018-04-23 Cellules différenciées à partir de cellules souches mésenchymateuses pour le traitement de lésions dermiques
PCT/EP2019/060342 WO2019206891A1 (fr) 2018-04-23 2019-04-23 Cellules différenciées de cellules souches mésenchymateuses pour le traitement de lésions dermiques

Publications (1)

Publication Number Publication Date
EP3784257A1 true EP3784257A1 (fr) 2021-03-03

Family

ID=62597417

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18305501.1A Withdrawn EP3560504A1 (fr) 2018-04-23 2018-04-23 Cellules différenciées à partir de cellules souches mésenchymateuses pour le traitement de lésions dermiques
EP19722530.3A Pending EP3784257A1 (fr) 2018-04-23 2019-04-23 Cellules différenciées de cellules souches mésenchymateuses pour le traitement de lésions dermiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP18305501.1A Withdrawn EP3560504A1 (fr) 2018-04-23 2018-04-23 Cellules différenciées à partir de cellules souches mésenchymateuses pour le traitement de lésions dermiques

Country Status (2)

Country Link
EP (2) EP3560504A1 (fr)
WO (1) WO2019206891A1 (fr)

Also Published As

Publication number Publication date
WO2019206891A1 (fr) 2019-10-31
EP3560504A1 (fr) 2019-10-30

Similar Documents

Publication Publication Date Title
WO2008156728A1 (fr) Traitement de maladies et de troubles à l'aide de cellules formant des colonies s'auto-renouvelant cultivées et soumises à une expansion in vitro
Gao et al. The immunosuppressive properties of non-cultured dermal-derived mesenchymal stromal cells and the control of graft-versus-host disease
US20060039991A1 (en) Biological tissue regenerative agent and method for preparing and using same
WO2011156784A1 (fr) Compositions et procédés pour le traitement de l'ischémie critique des membres inférieurs (cli) sans option
JP2015129180A (ja) 活性化白血球組成物
US9439950B2 (en) Activated leukocyte conditioned supernatant and uses for wound healing
Wang et al. Recent advances in the adjunctive management of diabetic foot ulcer: Focus on noninvasive technologies
US20150352151A1 (en) Activated leukocyte composition and uses for wound healing
Garg et al. Stem Cells and Regenerative Strategies for Wound Healing: Therapeutic and Clinical Implications
EP3560504A1 (fr) Cellules différenciées à partir de cellules souches mésenchymateuses pour le traitement de lésions dermiques
EP1848447B1 (fr) Agent de regeneration d'un tissu biologique et methode de preparation et d'utilisation
Panda et al. Stem cell-based tissue engineering approaches for diabetic foot ulcer: a review from mechanism to clinical trial
CN114901806A (zh) 细胞群以及其取得方法
Zhao et al. Transforming Growth Factor-β Partially Reversed the Immunosuppressive Effect of Mesenchymal Stem Cells in Mice
Phu et al. Long Term Rejuvenation of Facial Skin by Transplantation of Autologous Stromal Vascular Fraction and Pre-conditioned Matrix: A Clinical Study
KR20110032513A (ko) 조직 재생용 조성물
RU2780179C2 (ru) Происходящие из перинатальной ткани мезенхимальные стволовые клетки: способ их получения и применения
TWI493035B (zh) Human umbilical cord mesenchymal stem cells in vitro culture method, promote cell growth and wound healing of the relevant components of the manufacturing method and its application.
Anzalone et al. Wharton's Jelly Mesenchymal Stem Cells and Immune Modulation: Regenerative Medicine Meets Tissue Repair
Çelebi-Saltik et al. Stem Cell

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201021

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230630